Altogether, this work unveils TXN system as a novel target for BCP‐ALL therapy and encourages further preclinical studies aimed at testing the efficacy of the combinations of TXN system inhibitors with anti‐BCP‐ALL chemotherapeutics, as well as with targeted drugs. Here, TXN is linked to acute lymphoblastic leukemia.